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Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (MTB) that usually affects
the lungs leading to severe coughing, fever, and chest pains. Although current research in the past four
years has provided valuable insight into TB transmission, diagnosis, and treatment, much remains to be
discovered to effectively decrease the incidence of and eventually eradicate TB. The disease still puts a
strain on public health, being only second to HIV/AIDS in causing high mortality rates. This review will
highlight the history of TB as well as provide an overview of the current literature on epidemiology,
pathogenesis and the immune response, treatment, and control of TB. In this race to combat a disease
that knows no boundaries, it is necessary to have a conceptual and clear understanding of TB overall with
the hope of providing better treatment through novel and collaborative research and public health
efforts.
© 2015 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction: the history of tuberculosis from the 1800s to
the present
“Just sleep and eat nutritious foods” was the advice given to
patients in the 1800s infected with tuberculosis (TB), or formerly
known as consumption [1], an airborne disease that usually affects
the lungs leading to severe coughing, fever, and chest pains [2,3].
This mysterious disease, whose Latin-originated name describes
the rod shape of the bacillus, became better understood when the
German microbiologist Robert Koch announced that Mycobacte-
rium tuberculosis caused TB in 1882 [1]. This revolutionary ﬁnding,
along with the later discoveries of tuberculin in 1890 and the
Bacillus-Calmette Guerin (BCG) vaccine in 1908 and antitubercu-
losis drugs starting in 1943, offered hope for the eradication of a
disease deadlier than the plaque.td. This is an open access article uMortality rates signiﬁcantly declined from the early to mid-20th
century; however, funding for research dwindled and between
1970 and 1990, drug and vaccine developments slowed [1,3]. With
the onset of the AIDS pandemic and resistant strains, TB rates rose
once again, and with that, interest in TB research and prevention
[1]. Though by this time, the diagnostic and treatment tools
necessary to combat the disease were largely obsolete and strate-
gies to control and prevent the disease were developed, including
the Directly Observed Treatment Short-Course (DOTS) program in
1993, with the addition of a DOTS-plus program to address multi-
drug resistant (MDR) TB in 1998 [1,3].
Although current research in the past four years has provided
valuable insight into TB transmission, diagnosis, and treatment,
much remains to be discovered to effectively decrease the inci-
dence of and eventually eradicate TB [1,4]. The disease still puts a
strain on public health, being only second to HIV/AIDS in causing
high mortality rates [2]. It has been reported that in 2011 alone,
there were about 8.7 million new cases and 1.4 million deaths due
to TB [1,2,5], with about two billion people latently infected [3]. Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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epidemiology, pathogenesis, treatment, and control of TB, in order
to better understand the disease in hopes of providing better
treatment through novel research and public health efforts.
2. Epidemiology, transmission, diagnostic tools: prevalence,
airborne transmission, TST/IGRAs
There are certain risk groups that are more susceptible to get-
ting infected including: young adults (more commonly males),
those in developing countries, health care workers who are around
the disease frequently, and thosewhose immune systems areweak,
as in those who have HIV or smoke [2,4]. In fact, TB is the leading
cause of death in those infected with HIV and HIV-TB comorbidity
has been widely studied [4,6]. Additionally, foreign-born in-
dividuals and those who reside in impoverished areas or where
malnutrition is prevalent are more likely to get infected [2]. The
host's own deﬁciency in interleukin (IL)-12 promoting the T helper
(Th) 1 response may be another factor in the increased suscepti-
bility to infection [7]. There are other conditions that may pose a
high-risk for susceptibility to MTB infection such as diabetes,
ageing, long-term use of corticosteroids, TNF-a blockers, poly-
morphism in vitamin D receptors, polymorphism in IL-12 and IFN-g
genes. However, these other conditions will not be discussed in
detail here.
MTB infection is acquired by inhalation of infectious aerosol
particles released from close contacts [6,8]. A majority of in-
dividuals who inhale MTB mount an effective response in the lungs
leading to successful inhibition in the growth of MTB, resulting in
the bacteria becoming dormant; this condition is often referred to
as latent tuberculosis or LTBI [9]; immunocompetent latent in-
dividuals are infected with MTB but do not present symptoms and
do not transmit the disease to others [2,6]. It is well-known that 1/
3rd of the entire world's population is latently infected with MTB
[6]. From latent infection, the infection can progress to an active
state [5]. About 5e10% of LTBI cases are at risk to progressing from
infection to active (primary) TB [6]. Those with HIV and other
immunocompromised individuals, such as those with cancer or
currently taking immunosuppressing medication have a higher risk
of developing active TB.
TheWorld Health Organization (WHO) reported that “one-third
of the world's population has been infected with TB” [2]. Holding
true to Robert Koch's statement that the disease is deadlier than the
plaque or cholera [1,6], about 9 million people were infected with
TB and about 1.5 million succumbed to the disease in 2013 [2]. In
2004, TB was responsible for 2.5% of all deaths in the world [8]. The
household is often the site of exposure in high- and low-burden
countries, though infection rates are higher in areas such as hos-
pitals or prisons [4]. Prevalence of the disease in such settings de-
pends on virulence, innate immunity, and susceptibility.
While TB can be present in any society in any country, a majority
of those deaths reported, about 95%, occurred in low- and middle-
income countries where resources are more limited, with a ma-
jority of cases appearing in India and China [2,4]. Those with HIV
are most at-risk for getting infected with TB, and about 80% of HIV-
infected people with TB live in sub-Saharan Africa [4,8]. In contrast,
in low-burden countries like the United States, only 10% of people
with TB are infected with HIV; in 2008, only 12, 904 TB cases were
reported with the incidence being 4.2 per 100,000. While diag-
nostic advancements have been made in the past four years, 80% of
TB cases worldwide are concentrated in twenty-two countries [1]
twenty-seven countries including India, China, and Russia, are
responsible for about 85% of MDR TB cases [4]. Unfortunately, more
recent data is not available due to the limits of global surveillance
and reporting systems [8]. Additionally, there still remains anincomplete understanding how one person can acquire the disease
while another doesn't, though they are exposed to the same risk
factors, or how to better determine latent to active TB progression
[5,7].
Since a majority of people with TB have latent infection [6], the
development of new diagnostic and screening tools and standards
has become necessary in order to control the disease [9,10].
Interferon-gamma release assays (IGRAs) are used to diagnose LTBI,
although the tuberculin skin test (TST) still remains the most cost-
effective test [9]. The TSTand IGRAwork bymeasuring the response
of T cells to TB antigens [6].
2.1. TST
In the traditional TST, tuberculin puriﬁed protein derivative
(PPD) mix of proteins from TB are intradermally injected into a
person, causing a type IV delayed hypersensitivity skin reaction, if
the individual was either previously exposed to mycobacterial
proteins present in the vaccine or previously exposed to the
mycobacteria infection [9]. To determine if the person is infected
with TB, the size of the skin reaction is measured; the usual stan-
dard is between 48 and 72 h and a cut-off from 0.74 at 5 mm to
0.40 at 15 mm. However, the TST is known to lead to false-positive
responses in those who are BCG vaccinated and to false-negative
responses in immunosuppressed individuals.
2.2. IGRAs
The IGRAs are more sensitive and speciﬁc (81e88% compared to
70% sensitivity for the TST) [10]; however, they are expensive and
technical [4]. They detect the release of cytokine IFN-g from T cells
that react to antigens not found in the BCG vaccine [4,10]. A blood
sample is taken from an individual and the release of IFN-g is
measured. Guidelines constantly change for IGRA use. In Canada
and in some European countries, it has even been suggested that
IGRAs and the TST be used together to diagnose LTBI, but these tests
are not deﬁnitive [9,10].
Overall, having a better understanding of how the disease de-
velops in individuals from a latent to active TB by identifying risk
factors associated with high- and low-burden countries will help
lead to the development of better diagnostic tools and will improve
our understanding of the immune response in TB.
3. Pathogenesis and immune response: the interactions
between MTB and the host cell
de Martino et al. [7] describe the initial combat of TB once it
invades the host using the quote: “All is decided the ﬁrst day, which
gets the longest day”. Once the bacterium M. tuberculosis (MTB) is
inhaled via droplets spread through person-to-person contact,
macrophages can phagocytose and kill the bacilli. However, if the
bacilli are not killed, during that initial interaction, they can pro-
liferate within dendritic cells and alveolar macrophages at a rapid
rate, signaling the production of IL-1-a, IL-1b, and other host
proinﬂammatory cytokines.
This response is mediated by pattern recognition receptors
(PRRs) [7,11] expressed by macrophages and dendritic cells that
recognize pathogen-associated molecular patterns (PAMPS)
expressed on MTB [11]. Toll-like receptors (TLRs) help uptake MTB,
which induces an intracellular signaling cascade to produce the
cytokines. However, anti-inﬂammatory cytokines help the infection
by opposing host cell proinﬂammatory responses. During the initial
innate immune response, MTB proliferates within the host cell,
inducing cell death via the virulence factor ESX1 type VII secretion
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adaptive immune response [7,12].
In doing so, TB is a unique disease in that a detectable cellular
response occurs after a much longer time-about 2e12 weeks after
infection [4,6]. Dendritic cells transport mycobacteria to the medi-
astinal lymph node (MLN), where antigen-presenting cells (APCs)
activate T cells [13]. Bacilli are loaded ontomajor histocompatibility
complex (MHC) class II, priming Th 1 IFN-g-secreting antigen-
speciﬁc T cells that move to the lung. With the activation of the
adaptive immune response, both effector CD4þ and CD8þ T-cells
are induced [7,13]; MTB can accumulate mutations during this time
[7] and cytokines are continually produced, such as IFN-g [13].
Mycobacteria can change the expression of their genes and there-
fore their surface antigens to evade T-cell recognition [7].
After the continuous production of cytokines, T cells limit the
mobility of macrophages and activate them for enhanced function
[13]. A type 1 “immune granuloma”, composed of macrophages,
neutrophils, monocytes, dendritic cells, and T cells, is then formed
in the lung that might control MTB growth, as some studies have
shown, though it is now thought that MTB can hijack the granu-
loma for its own beneﬁt. MTB alter the immune response of the
granuloma through IL-10, whichworks to suppress the activation of
T cells and macrophages. Interestingly, knockout (KO) studies in IL-
10 mice demonstrate a small reduction in bacterial load, suggesting
that, through evolution, MTB might utilize multiple pathways for
its own beneﬁt. A “chronic granuloma”, that additionally is
composed of foamy and epitheloid macrophages and a ﬁbrotic
encapsulation, can result, leading to the morphological and func-
tional alterations of the granuloma; these alterations are highly
dynamic and can vary between individuals and even within an
individual, though it is unclear whether these alterations are
mediated by the host or by the bacteria.
There is a delay between MTB infection and T cell response
[6,7,13]. Up until this stage, TB is suppressed to an inactive, or latent
form, where infected individuals do not present with symptoms
and cannot transmit the disease [6,7]. In the case of LTBI, as
mentioned, mycobacterial growth is controlled (though bacterial
replication does occur) by adaptive immunity before the disease
can develop [4], by containing MTB within granulomas [6,11,13] or
by nitric oxide (NO) in mice or antimicrobial peptides in humans
[14]. Latently infected people display healed granulomas, “marked
by central calciﬁcation in conjunction with ﬁbrotic encapsulation
containing no detectible bacilli” [4,13]. Encapsulation may prevent
bacterial escape or limit immune intrusion, but this is unclear [13].
However, at some point, even after many years of latency,
exogenous factors [14], like the secreted protein resembling
resuscitation-promoting factor (Rpf), can be activated, where bac-
teria are reverted from a suppressed state to an active state and can
resume cell division [7,12]. Rpf gene deletions might be a factor in
the progression from latency to reactivation [12], where it has been
shown that RpfB and RpfE are important for resuscitation [14].
Additionally, toxin-antitoxin (TA) gene pairs, or plasmid mainte-
nance factors [14], encoded by MTB play a role in determining the
switch from latency to reactivation by producing a toxin that gets
neutralized by antitoxin that is then degraded; the toxin can then
kill the cell [12,14]. Although, the regulation between latent and
active TB and the actual state of the bacterium during latency re-
mains to be further studied [14].
It is at the adaptive immune stage that TB can clinically manifest
in multiple ways, once it switches from a latent to active state;
clinical manifestation depends on where mycobacteria proliferate
[4,6,14]. Proliferation can occur in the spine, hips, and the gastro-
intestinal tract, but in most cases, proliferation occurs in the lung;
about 85% of TB patients present with pulmonary symptoms [6].
Clinical symptoms of pleural TB include chronic cough, night sweat,blood-tinged sputum, weight loss, shortness of breath, fever, chest
pain, and pleurisy (or inﬂammation of the pleura membrane sur-
rounding the lungs) [4,6]. Cloudy patches and pleural effusion can
appear in chest radiographs [6]. However, elderly people might not
show these signs and symptoms [4].
In order to study the interaction between the host immune
response and the MTB, several animal models are used, including
themurine (or mouse), guinea pig, rabbit, andmonkeymodels [14].
The preferred animal models to date are the murine and monkey
(or macaque) models [13e15]. While the murine model is more
cost-effective and more easily available than the macaque model, it
lacks a paucibacillary state present in human latent infection that
the macaque model does possess [14,15]. Although the two are
different and cannot imitate human TB perfectly due to a variety of
factors and complexities, ﬁndings using each combined have pro-
vided valuable insight into TB characteristics, pathogenesis, and
treatment [14,15]. Here, the focus will be on the contribution of the
murine and macaque models to our understanding of human TB
latency, granulomas, treatment [13,14], and HIV co-infection
[14,15].
In the murine model, expression studies conducted in 2004 that
analyzed the change in gene expression proﬁles during MTB
chronic infections in vivo have shown that genes change their
transcription levels in the lungs, similar to in vitro dormancy
models [14]. Earlier studies conducted using the Cornell model of
dormancy developed around the 1960s have shown that mice
treated with certain drugs can develop reactivation; without this
treatment, an actively replicating dormant population is present in
mice. Unlike the murine model, clinically latent infection in the
cynomolgus model can be directly detected and reactivation does
not require the drug regimen needed by the Cornell model. Latent
infection granulomas from the macaque model more closely
resemble those in humans [14,15], which could add to our under-
standing of how humans with latent disease respond to antibiotic
treatments [14] and could translate frommurine studies to humans
about the role of granulomas in preventing and controlling the
spread of MTB in the future [13].
Translational studies should be interpreted with caution [14], as
modeling HIV, a high risk factor associated with TB, has proved
challenging as mice are not hosts of HIV [15]. Although humanized
and BLT (bone marrow, liver, thymic) mice can be used, the ma-
caquemodel can be infectedwith a retrovirus similar to HIV, simian
immunodeﬁciency virus (SIV). Recently, MTB antibiotic treatment
was shown to reduce HIV transgene expression in HIV transgenic
mice, while mice infected with MTB demonstrated an increase in
HIV expression at bacterial replication sites and sites of inﬂam-
mation. The MTB/SIV co-infection macaque model has played an
important role in investigating the cellular and molecular mecha-
nisms of TB reactivation by HIV infection and in the immunologic
and microbial factors associated with MTB and HIV co-infection.
Using this model, an inverse relationship between risk of MTB
infection and CD4 T cell levels has been observed: when the former
increases, that latter decreases; this ﬁnding has great implications
for highly susceptible HIV patients [15]. Taken together, these
ﬁndings can help in the creation of novel treatment regimens.
4. Treatment and vaccines: antituberculosis drugs, BCG
vaccine, and drug resistance
The course of TB treatment depends on whether the individual
is in the latent or active stage and on his or her probability of risk. If
a person has recently come into contact with an infected individual
and a TST is negative, LTBI treatment can be started and continued if
the TST result is positive after a 12-week window; HIV patients
usually continue treatment though the TST result might be negative
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multiple drugs, with an intensive initial 2-month phase followed by
a slower 4- to 6-month continuation phase [4].
Themain antituberculosis drugs used in the chemotherapy of TB
are: isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and either
ethambutol (EMB) or streptomycin (SM) [4,6]. Depending on the
status of the exposed individual, the regimen changes and can be
complex to follow. A drug regimen chart created by the Centers for
Disease Control and Prevention (CDC) outlines the intervals and
doses for drug treatment during speciﬁc phases [8]. For example, if
the MTB isolate is fully susceptible, either EMB or SM are dis-
continued, and PZA can be discontinued after two months of
treatment. INH and RIF are continued for four months. Treatment
can last from six to nine months [6,8] or even up to twenty months
[6].
In addition to the ﬁve main antituberculosis drugs, the Myco-
bacterium bovis BCG vaccine is the current vaccine used to mimic
the natural immune response to infection [16]. Although the BCG
vaccine has been widely administered for more than eighty years
and strongly induces Th 1 cells, its efﬁcacy is highly variable, ac-
cording to a recent review by Andersen [16]. It has only limited
protection in adults with pulmonary TB in high-TB-endemic re-
gions. The need for a better vaccine is evident; however, limitations
in our knowledge of which aspects of BCG immunity are important
for long-lasting protection against MTB prevent successful efforts.
Over the past ten years, there has been a race to develop a better
vaccine, and the Modiﬁed-Vaccinia-Ankara (MVA) 85A vaccine was
introduced [16]. Unfortunately, excitement over MVA85A clinical
trials was undermined as the vaccine could not improve protection
against TB.
Why is there such a complex regimen involving multiple drugs
to treat TB? The answer lies in the fast spontaneous mutation rate
of MTB [4,6]. Although drug susceptibility tests are always per-
formed to monitor resistance [8], previous treatment, not
completing treatment, not complying with treatment, and
improper or inadequate regimens can confer drug resistance
[2,6,8]. According to the fourth Global Drug Resistance Surveillance
Project conducted from 2002 to 2007 by the WHO [2], about 17% of
new resistance cases had resistance to at least one antituberculosis
drug and about 2.9% hadmulti-drug resistance (MDR), or resistance
to at least INH and RIF. INH resistance is the most common type [6].
AWHO report in 2009 estimated about 3.3% of TB cases were MDR.
Drug resistance continues to pose a major health concern. In
some areas, such as Azerbaijan, it was reported in 2007 that 56.3%
of new cases were resistant to any drug and 22.3% were MDR [8].
Annual mortality was estimated in 2009 to be 150,000 worldwide
[6], with about 480,000 developing MDR-TB in 2013 with the most
cases found in India, China, and Russia [2]. In recent years,
extensive-drug resistance (XDR), or MDR plus resistance to second-
line drugs, has become a worldwide concern, with about 24% of
XDR cases among MDR cases in Russia in 2006 [8], and accounting
for about 9% of MDR cases in the world in 2013 [2].5. Control of TB: achievements, DOTS, Stop TB Strategy
Fortunately, the WHO reports that some countries have
continued to havemajor declines in TB cases [2]; in Cambodia alone
the TB prevalence fell by about 50%. Due to diagnostic and treat-
ment efforts, about 37 million lives were saved between 2000 and
2013. [2]. However, maintaining this success has mostly been
complicated by HIV, MDR, XDR, the inefﬁcacy of the BCG vaccine,
false positive screening tests, non-compliance to treatment regi-
mens, the complexity of MTB, and the stall in developing novel
therapeutics.In some countries, like India, China, and Russia, TB rates are only
dropping slowly and still remain high [2]. To address this concern,
an additional treatment regimen is undergone by patients called
directly observed therapy short-term (DOTS), which closely mon-
itors treatment adherence and completion [6], with the goal of
efﬁciency and cost-effectiveness [1]. With the emergence of MDR-
TB, DOTS-plus was initiated as a more rigorous treatment strategy
[1,4].
The WHO drafted a Stop TB Strategy [2], which outlines six aims
to be implemented by all countries to reduce TB on both local and
national scales, with the overall goal of enhancing TB treatment,
health care experiences, and research. It is the world's hope that at
least some of these aims will be achieved in the near future.
6. Conclusion: where are we and where do we need to go?
Understanding TB has progressed from the advice in the 1800s
to “just sleep and eat nutritious foods” [1]. IGRAs can better di-
agnose LTBI than TST [4,10] and the macaque model can provide
insight into HIV co-infection as it closely resembles human TB
[13e15]. However, a more complete understanding of latent
development [3,4,6,7,11e14] and of the protective and pathological
immune responses and interactions in TB [4,6,7,11e13,16] are
greatly needed in order to develop efﬁcacious drugs and vaccines
[6,16]. Possibly measuring an individual's transcriptional signature
could allow for a more personalized monitoring of the disease. This
could help reduce the number of MDR cases [2,4,6,8] and might be
a better alternative to DOTS therapy [1,4,6]. It is remarkable that
this disease has posed a threat to public health since the 1800s, yet
therapeutic advancements have been futile and slow. In this race to
combat a disease that knows no boundaries, it is necessary to have
a conceptual and clear understanding of TB overall. This can only be
enforced if collaborative efforts among research, public health of-
ﬁcials, primary care professionals, and the general public continue
to push the boundaries of our current knowledge, mitigating the
global burden of TB.
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